Compare UFPT & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UFPT | TYRA |
|---|---|---|
| Founded | 1963 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 1996 | 2021 |
| Metric | UFPT | TYRA |
|---|---|---|
| Price | $269.08 | $30.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | ★ $289.00 | $47.50 |
| AVG Volume (30 Days) | 159.6K | ★ 1.1M |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.44 | N/A |
| EPS | ★ 2.24 | N/A |
| Revenue | ★ $602,797,000.00 | N/A |
| Revenue This Year | $8.12 | N/A |
| Revenue Next Year | $5.72 | N/A |
| P/E Ratio | $121.59 | ★ N/A |
| Revenue Growth | ★ 19.50 | N/A |
| 52 Week Low | $173.86 | $9.96 |
| 52 Week High | $275.20 | $40.65 |
| Indicator | UFPT | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 77.77 | 50.92 |
| Support Level | $205.96 | $24.77 |
| Resistance Level | N/A | $31.57 |
| Average True Range (ATR) | 10.04 | 1.88 |
| MACD | 3.25 | 0.45 |
| Stochastic Oscillator | 94.48 | 73.73 |
UFP Technologies Inc is a contract development and manufacturing organization that specializes in single-use and single-patient medical devices. The company manufactures its products by converting raw materials using laminating, molding, radio frequency, and impulse welding, and fabricating manufacturing techniques. It is an important link in the medical device supply chain and a valued outsource partner to many of the top medical device manufacturers in the world. The company's single-use and single-patient devices and components are used in a wide range of medical devices, disposable wound care products, infection prevention, minimally invasive surgery, wearables, orthopedic soft goods, and orthopedic implant packaging.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.